Welcome to our dedicated page for Assembly Biosciences news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Biosciences stock.
Assembly Biosciences, Inc. (NASDAQ: ASMB) is a public clinical-stage biotechnology company dedicated to advancing innovative therapies for serious viral diseases. The company focuses on two key platform programs: the treatment of Hepatitis B virus (HBV) infection and the development of novel oral live biotherapeutics for disorders associated with the microbiome.
In the HBV program, Assembly Biosciences is pioneering a new class of oral therapeutics aimed at increasing cure rates for patients with chronic HBV. The company has developed several drug candidates that inhibit various steps in the HBV lifecycle, including novel core protein allosteric modulators (CpAMs). These small molecules target and modulate the HBV core protein, a crucial component in the virus's replication process.
The microbiome program is designed to address diseases linked to dysbiosis, an imbalance in the microbial community of the gut. Assembly Biosciences employs a robust strain identification and selection process, methods for strain isolation and growth under Good Manufacturing Practices (GMP), and a patent-pending delivery system known as GEMICEL®. This system ensures targeted delivery of live biotherapeutics to specific areas in the gastrointestinal tract.
Recent achievements for Assembly Biosciences include a long-term partnership with Gilead Sciences to accelerate the development of their antiviral pipeline. This collaboration is expected to enhance the company's financial and scientific resources, positioning them to achieve critical milestones and deliver innovative treatments to patients.
Financial results for the third quarter of 2023 highlighted the company's ongoing progress, including the advancement of multiple antiviral candidates targeting herpesviruses, HBV, and hepatitis delta virus (HDV). Assembly Biosciences also announced leadership enhancements, including the appointment of Dr. Anuj Gaggar as Chief Medical Officer.
Looking ahead, Assembly Biosciences plans to have four candidates in clinical studies by the end of 2024. These include the initiation of trials for ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor, and the development of ABI-6250, an orally bioavailable small molecule for treating chronic HDV.
For more information, visit assemblybio.com.
Assembly Biosciences (Nasdaq: ASMB) has shared Phase 1a clinical data for its HBV core inhibitor, ABI-4334, which shows promising efficacy against viral replication and cccDNA formation. The company is actively considering partnering options for its core inhibitor portfolio, aiming to advance the development of these therapies. In addition, Assembly Bio is prioritizing its antiviral pipeline, including ABI-5366 for high-recurrence genital herpes, with plans to enter clinical trials in the first half of 2024. The financial outlook remains strong, with an estimated cash runway extending into Q3 2024. CEO Jason Okazaki highlighted the need for longer-duration studies to validate the efficacy of core inhibitors. Overall, the results suggest a strong foundation for future development in HBV treatments.
Assembly Biosciences, Inc. (Nasdaq: ASMB) updated its progress on investigational hepatitis B virus (HBV) core inhibitors ABI-3733 and ABI-4334. The company is prioritizing ABI-4334 based on its superior potency and clinical profile while pausing ABI-3733 due to observed toxicity concerns. Preliminary data from ABI-3733’s Phase 1b trial showed significant viral suppression in patients. Financially, the company reported a net loss of $93.1 million for 2022, an improvement from $129.9 million in 2021. As of December 31, 2022, cash reserves were $91.6 million, projected to fund operations into mid-2024.
Assembly Biosciences (ASMB) has announced the selection of ABI-5366 as a development candidate for its long-acting HSV-2 helicase inhibitor program. This selection marks a significant advancement since the company expanded its research focus beyond hepatitis B. The drug, designed for long-acting administration, shows favorable pharmacokinetics and potential for at least monthly dosing. Current HSV-2 therapies are partially effective, and ABI-5366 aims to enhance adherence and efficacy. The company plans to file with the FDA in the first half of 2024 and is eager to present more data at scientific conferences this year.
Carver Biosciences, a Boston-based biotech firm focused on CRISPR/Cas13 antivirals, has established its Scientific Advisory Board (SAB). Dr. Cameron Myhrvold will chair the SAB, with Dr. Uri Lopatin, Dr. Olivia Merkel, and Dr. Neville Sanjana joining as members. Dr. Lopatin brings significant experience from founding Assembly Biosciences (NASDAQ:ASMB) and Pardes Biosciences (NASDAQ:PRDS), having raised over $600 million for novel therapies. The new board aims to enhance Carver's pipeline and advance its clinical programs.
FAQ
What is the current stock price of Assembly Biosciences (ASMB)?
What is the market cap of Assembly Biosciences (ASMB)?
What does Assembly Biosciences, Inc. specialize in?
What are the main programs of Assembly Biosciences?
What is the HBV program at Assembly Biosciences?
What is the microbiome program at Assembly Biosciences?
What recent achievements has Assembly Biosciences made?
What are the anticipated milestones for Assembly Biosciences in 2024?
How does Assembly Biosciences' GEMICEL® delivery system work?
What is the significance of the partnership with Gilead Sciences?
Who is the CEO of Assembly Biosciences?
Where can I find more information about Assembly Biosciences?
